You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
白雲山(600332.SH):擬參設廣藥基金二期
格隆匯 07-25 20:59

格隆匯7月25日丨白雲山(600332.SH)公佈,公司擬作為有限合夥人以自有資金出資14.985億元(人民幣,下同)參與設立廣州廣藥基金二期股權投資合夥企業(有限合夥)(擬定名,具體以企業登記機構核准的名稱為準,“廣藥基金二期”、“基金”),佔廣藥基金二期認繳出資總額的99.90%。

廣藥基金二期的管理人為廣州廣藥資本私募基金管理有限公司(“廣藥資本”),廣藥資本是本公司控股股東廣州醫藥集團有限公司(“廣藥集團”)持股80%的控股子公司。廣藥資本作為執行事務合夥人、基金管理人和普通合夥人認繳出資150.00萬元。本公司副董事長程寧女士擔任廣藥資本的董事長。因此,本公司本次認購廣藥基金二期份額構成關聯交易。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account